
2024 No. 36
Dangerous Drugs
The Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2024
Made 6th March 2024
Coming into operation 27th March 2024
The Department of Health, makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971 as adapted by sections 7(9), 31(4) and 38 of that Act and now vested in it and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 31(3) of that Act.
Citation, commencement and interpretation
1 

(1) These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2024 and shall come into operation on 27th March 2024.
(2) The Interpretation Act (Northern Ireland) 1954 shall apply to these Regulations as it applies to an Act of the Northern Ireland Assembly.
Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
2 

(1) The Misuse of Drugs Regulations (Northern Ireland) 2002 are amended as follows.
(2) In paragraph 1(a) of Schedule 1 (Controlled Drugs subject to the requirements of Regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—
(a) after “Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)” insert “Brorphine”;
(b) after “Bufotenine” insert “Butonitazene”;
(c) after “Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Clonitazene”;
(d) after “Concentrate of poppy-straw” insert “Cumyl-PeGaClone”;
(e) after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—“DiphenidineEphenidineEthyleneoxynitazene”;
(f) after “Etizolam” insert—“Etodesnitazene (etazene)Etonitazene”;
(g) after “Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Flunitazene”;
(h) after “Isopropylphenidate (IPP or IPPD)” insert “Isotonitazene”;
(i) after “Methcathinone” insert “Methoxyphenidine”;
(j) after “Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)” insert—“Metodesnitazene (metazene)Metonitazene”;
(k) after “Propylphenidate” insert “Protonitazene”;
(l) after “1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)” insert—“N-Desethyl etonitazeneN-DesethylisotonitazeneN-Desethyl protonitazene”;
(m) after “4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR)” insert—“N-Piperidinyl-etonitazene (etonitazepipne)N-Pyrrolidino-etonitazene (etoniazepyne)N-Pyrrolidino protonitazene”.
(3) In paragraph 1 of Schedule 2 (Controlled Drugs subject to the requirements of regulations 14, 15, 16, 16A, 18, 19, 20, 21, 23, 26 and 27) omit “Clonitazene” and “Etonitazene”.
(4) In paragraph 1 of Part 1 of Schedule 4 (which specifies controlled drugs subject to the requirements of regulations 22, 23, 26 and 27) after “Pyrovalerone” insert “Remimazolam”.
Sealed with the Official Seal of the Department of Health on 6th March 2024.
(L.S.)Cathy Harrison
A senior officer of the Department of Health
